دورية أكاديمية
أعرض في EDS

Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.

التفاصيل البيبلوغرافية
العنوان: Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
المؤلفون: Steppich B; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Dobler F; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Brendel LC; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Hessling G; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Braun SL; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Steinsiek AL; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Deisenhofer I; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany., Hyseni A; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands., Roest M; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, Utrecht, The Netherlands., Ott I; Deutsches Herzzentrum der Technischen Universität München, Lazarettstr 36, 80636, Munich, Germany. ott@dhm.mhn.de.
المصدر: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2017 May; Vol. 43 (4), pp. 490-497.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print Cited Medium: Internet ISSN: 1573-742X (Electronic) Linking ISSN: 09295305 NLM ISO Abbreviation: J Thromb Thrombolysis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Dordrecht ; Norwell, MA] : Kluwer Academic Publishers, c1994-
مواضيع طبية MeSH: Atrial Fibrillation/*drug therapy , Factor Xa Inhibitors/*pharmacology , Platelet Activation/*drug effects, Aged ; Anticoagulants/therapeutic use ; Drug Administration Schedule ; Factor Xa Inhibitors/therapeutic use ; Female ; Heparin/administration & dosage ; Humans ; Male ; Middle Aged ; Pyrazoles/administration & dosage ; Pyrazoles/pharmacology ; Pyridones/administration & dosage ; Pyridones/pharmacology ; Rivaroxaban/administration & dosage ; Rivaroxaban/pharmacology
مستخلص: Rivaroxaban and Apixaban, increasingly used for stroke prevention in non-valvular atrial fibrillation (AF), might impact platelet reactivity directly or indirectly. By inhibition of Factor Xa (FXa) they preclude not only generation of relevant thrombin amounts but also block signalling of FXa via protease activated receptors. However, weather FXa-inhibition affects platelet haemostasis remains incompletely known. One hundred and twenty-eight patients with AF on chronic anticoagulation with either Rivaroxaban or Apixaban for at least 4 weeks were included in the study. In a time course group (25 on Rivaroxaban, 13 on Apixaban) venous blood samples were taken before NOAC medication intake in the morning as well as 2 and 6 h afterwards. In 90 patients (Rivaroxaban n = 73, Apixaban n = 17) blood samples were drawn during left atrial RFA procedures before as well as 10 and 60 min after the first heparin application (RFA group). Platelet reactivity analyzed by whole blood aggregometry (Multiplate Analyzer, Roche) in response to ADP, Collagen, TRAP and ASPI (arachidonic acid) was not altered by Rivaroxaban or Apixaban neither in the time course nor in the RFA group. Moreover, soluble P-selectin, Thrombospondin, von Willebrand Factor and beta thromboglobulin plasma levels, measured by ELISA, showed no statistically significant changes in both clinical settings for either FXa-inhibitor. The present study fails to demonstrate any significant changes on platelet reactivity in patients with AF under chronic Rivaroxaban or Apixaban medication, neither for trough or peak levels nor in case of a haemostatic activation in vivo as depicted by RFA procedures.
References: Thromb Res. 2016 Feb;138:63-68. (PMID: 26610745)
Thromb Res. 2010 Jul;126(1):39-43. (PMID: 20466409)
J Intern Med. 2014 Jan;275(1):1-11. (PMID: 24112453)
J Thromb Thrombolysis. 2012 Oct;34(3):291-6. (PMID: 22528328)
Pharmacol Res. 2013 Aug;74:49-55. (PMID: 23714416)
Open Heart. 2016 Jan 18;3(1):e000279. (PMID: 26848392)
J Thromb Haemost. 2016 Oct;14 (10 ):1908-1916. (PMID: 27513692)
Thromb Res. 2012 Oct;130 Suppl 1:S44-6. (PMID: 23026660)
Arch Intern Med. 2012 Mar 12;172(5):397-402. (PMID: 22231617)
PLoS One. 2016 Feb 11;11(2):e0149077. (PMID: 26867010)
Circ Arrhythm Electrophysiol. 2014 Aug;7(4):576-82. (PMID: 24970293)
Eur Heart J. 2008 Jun;29(12 ):1504-9. (PMID: 18467322)
Int J Cardiol. 2013 Sep 10;167(6):2449-55. (PMID: 22989603)
Chest. 2003 Sep;124(3 Suppl):18S-25S. (PMID: 12970120)
J Am Coll Cardiol. 2013 Aug 27;62(9):777-81. (PMID: 23747777)
N Engl J Med. 2009 Sep 17;361(12):1139-51. (PMID: 19717844)
Blood. 1994 Dec 1;84(11):3715-23. (PMID: 7949127)
Blood. 2011 May 5;117(18):4686-7. (PMID: 21546469)
J Thromb Thrombolysis. 2016 Aug;42(2):161-6. (PMID: 26961375)
J Thromb Thrombolysis. 2015 Oct;40(3):340-6. (PMID: 26184605)
Blood Coagul Fibrinolysis. 2016 Dec;27(8):882-885. (PMID: 26757012)
Thromb J. 2014 Aug 28;12:18. (PMID: 25228850)
Blood. 2014 Apr 3;123(14):2153-6. (PMID: 24458436)
J Invasive Cardiol. 2009 May;21(5):247-54. (PMID: 19411729)
Blood. 2011 May 5;117(18):4946-52. (PMID: 21368290)
Am J Cardiol. 2015 Jan 1;115(1):47-51. (PMID: 25456870)
Medicine (Baltimore). 2016 Apr;95(14):e3037. (PMID: 27057830)
Pharmacol Res. 2016 Nov;113(Pt A):484-489. (PMID: 27693274)
فهرسة مساهمة: Keywords: Atrial fibrillation; FXa-inhibitors; Platelet aggregation
المشرفين على المادة: 0 (Anticoagulants)
0 (Factor Xa Inhibitors)
0 (Pyrazoles)
0 (Pyridones)
3Z9Y7UWC1J (apixaban)
9005-49-6 (Heparin)
9NDF7JZ4M3 (Rivaroxaban)
تواريخ الأحداث: Date Created: 20170320 Date Completed: 20170417 Latest Revision: 20181113
رمز التحديث: 20221213
DOI: 10.1007/s11239-017-1495-z
PMID: 28316004
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-742X
DOI:10.1007/s11239-017-1495-z